Navigation Links
Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
Date:1/30/2009

SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) confirmed today that it has received a notice from Amylin shareholder Icahn Capital LP and affiliated funds announcing their intent to nominate a slate of five directors to stand for election at the Company's 2009 annual meeting. The notice from the Icahn group also states their intent to submit a proposal for shareholder approval requesting that the Company reincorporate in the state of North Dakota.

In addition, the Company received a separate notice today from Amylin shareholder Black Bear Fund I, L.P. that it, together with its investment advisor Eastbourne Capital Management, L.L.C. and its controlling owner and managing member Richard J. Barry, also intends to nominate a separate slate of five directors to stand for election at the Company's 2009 annual meeting.

As previously disclosed, Amylin's Corporate Governance Committee is engaged in a process to recommend a slate for election at the Company's annual meeting. Once the process has been completed, Amylin's Board of Directors will formally recommend a slate of nominees that it believes will act in the best interest of all shareholders.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

Additional Information and Where to Find It

This release may be deemed to be solicitation material in respect of a proxy contest for the election of directors to the Board of Directors of Amylin. Amylin will be filing a proxy statement with the Securities and Exchange Commission ("SEC"). INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and securityholders will be able to receive the proxy statement and other relevant documents free of charge at the SEC's Web site at www.sec.gov or from Amylin Investor Relations at 9360 Towne Centre Drive, San Diego, California 92121.

Participants in Solicitation

Amylin and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of a proxy contest for the election of directors to the Board of Directors of Amylin. Information regarding the interests of Amylin's directors and executive officers in the proxy contest will be included in Amylin's definitive proxy statement.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017   Boston Biomedical , an ... to target cancer stemness pathways, will feature data from ... at the 2017 ASCO Gastrointestinal Cancers Symposium, held from ... Napabucasin is an orally-administered investigational agent ... i Cancer stem cells (CSCs) possess the property ...
(Date:1/18/2017)... ... 2017 , ... Whitehouse Labs has furthered its efforts towards ... (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has more ... 2017. Extractable & Leachable evaluations have become increasingly more vital to successful product ...
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, LLC, announced it ... and genetic testing lab equipment from two different leading institutes. This highly specialized laboratory ... of the United States. This 1-day online auction will take place on BidMed’s ...
(Date:1/18/2017)...  Caris Life Sciences, a leading innovator in ... private funder of pancreatic cancer research, are collaborating ... of immunotherapy in the treatment of pancreatic cancer. ... identify potential trial candidates based on biomarker expression ... study investigators. The Lustgarten Foundation is a sponsor ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced ... "Digital Life Alliance" established by iCarbonX, the ... to build a "Global Digital Health Ecosystem that ... a combination of individual,s biological, behavioral and psychological ... agreement between the companies, SomaLogic will provide proteomics ...
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
Breaking Biology News(10 mins):